Leflunomide Tablet
Product Images NDC 23155-044

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Leflunomide (NDC 23155-044). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Heritage Pharmaceuticals Inc. D/b/a Avet Pharmaceuticals Inc., these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Cfa52b95 F6ee 4a2c A320 E190f716d33b 01

Chemical structure of leflunomide showing its molecular framework including a trifluoromethyl-substituted phenyl ring and isoxazole ring system.*

FDA Label Image

Cfa52b95 F6ee 4a2c A320 E190f716d33b 02

Chemical structure diagram of teriflunomide, which is the active metabolite of leflunomide.*

FDA Label Image

Cfa52b95 F6ee 4a2c A320 E190f716d33b 03

Bar chart showing the percentage of ACR 20 responders at endpoint for three clinical trials of leflunomide. Trial 1 (12 months) compares leflunomide, methotrexate, and placebo; Trial 2 (6 months) compares leflunomide, sulfasalazine, and placebo; Trial 3 (12 months) compares leflunomide and methotrexate. Percentages range from about 18.6% to 56.6% across treatments.*

FDA Label Image

Cfa52b95 F6ee 4a2c A320 E190f716d33b 04

A line graph titled 'Trial 1 ACR Responders Over Time' showing the percentage of responders over 12 months. The graph compares three groups labeled PL, MTX, and LEF, with LEF showing the highest response rate over time, followed by MTX, and then PL. The x-axis represents months (0 to 12), and the y-axis represents the percentage of responders (from -10% to 70%).*

FDA Label Image

Cfa52b95 F6ee 4a2c A320 E190f716d33b 05

A bar chart titled 'Change in Sharp Score' comparing the progression of disease measured over three clinical trials of varying durations (12 months, 6 months, 12 months). The chart presents data for four treatment groups: Leflunomide (L), methotrexate (M), sulfasalazine (S), and placebo (P), with bars indicating progression values for each trial. The vertical axis shows progression values ranging from -10 to 8, with progression increasing downwards.*

FDA Label Image

Cfa52b95 F6ee 4a2c A320 E190f716d33b 06

A bar chart titled 'Change in Functional Ability Measure' showing improvement measured by HAQ Disability Index across three trials with durations of 6 to 12 months. The chart compares Leflunomide, Methotrexate, Placebo, and Sulfasalazine effects on functional ability, with bars indicating changes ranging from approximately -0.05 to -0.56 in improvement values.*

FDA Label Image

Cfa52b95 F6ee 4a2c A320 E190f716d33b 07

FDA Label Image

Cfa52b95 F6ee 4a2c A320 E190f716d33b 08

Label for Leflunomide Tablets USP, 10 mg, oral tablets. The package contains 30 tablets and is marked Rx only. Labeler is Avet Pharma, a division of Heritage Pharmaceuticals Inc. The label includes storage instructions, warnings, and a barcode.*

FDA Label Image

Cfa52b95 F6ee 4a2c A320 E190f716d33b 09

Leflunomide Tablets USP 20 mg oral tablets packaging label by Heritage Pharmaceuticals Inc. d/b/a Avet Pharmaceuticals Inc. The label indicates the strength as 20 mg with 30 tablets per package and includes storage instructions and warnings.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.